Close Menu

NEW YORK (GenomeWeb) – Biocartis announced today that it has received CE-IVD marking for two liquid biopsy tests to detect RAS mutations in circulating tumor DNA from patients with metastatic colorectal cancer. The tests are the Belgian molecular diagnostics firm's first liquid biopsy assays to receive CE-IVD marking. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.